BRPI0506496B8 - composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese - Google Patents

composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese

Info

Publication number
BRPI0506496B8
BRPI0506496B8 BRPI0506496A BRPI0506496A BRPI0506496B8 BR PI0506496 B8 BRPI0506496 B8 BR PI0506496B8 BR PI0506496 A BRPI0506496 A BR PI0506496A BR PI0506496 A BRPI0506496 A BR PI0506496A BR PI0506496 B8 BRPI0506496 B8 BR PI0506496B8
Authority
BR
Brazil
Prior art keywords
injection site
cyclodextrin
sulfobutylether
emesis
treatment
Prior art date
Application number
BRPI0506496A
Other languages
English (en)
Inventor
Christopher Adami Roger
David Frederick
Ann Wood Julia
Original Assignee
Pfizer Prod Inc
Pah Usa 15 Llc
Zoetis P Llc
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34910697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0506496(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc, Pah Usa 15 Llc, Zoetis P Llc, Zoetis Services Llc filed Critical Pfizer Prod Inc
Publication of BRPI0506496A publication Critical patent/BRPI0506496A/pt
Publication of BRPI0506496A8 publication Critical patent/BRPI0506496A8/pt
Publication of BRPI0506496B1 publication Critical patent/BRPI0506496B1/pt
Publication of BRPI0506496B8 publication Critical patent/BRPI0506496B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

CONSERVANTES ANTIMICROBIANOS PARA OBTENÇÃO DE FORMULAÇÃO DE MULTIDOSE USANDO BETA-CICLODEXTRINAS PARA FORMAS DE DOSAGEM LÍQUIDAS. A presente invenção refere-se a composições farmacêuticas contendo uma quantidade terapeuticamente eficaz de um Ingrediente Farmacêutico Ativo ("API'), uma ciclodextrina farmaceuticamente aceitável e um conservante farmaceuticamente aceitável. A invenção refere-se também a composições farmacêuticas dos compostos da Fórmula (I) em que R2 é selecionado do grupo consistindo em metila, etila, isopropila, sec-butila e terc-butila e uma ciclodextrina e um conservante farmaceuticamente aceitáveis. Fórmula (I): em particular, a invenção refere-se a composições farmacêuticas do composto da Fórmula Ia, e uma ciclodextrina e um conservante farmaceuticamente aceitáveis.
BRPI0506496A 2004-01-30 2005-01-17 composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese BRPI0506496B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54089704P 2004-01-30 2004-01-30
PCT/IB2005/000100 WO2005082416A2 (en) 2004-01-30 2005-01-17 Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms

Publications (4)

Publication Number Publication Date
BRPI0506496A BRPI0506496A (pt) 2007-02-13
BRPI0506496A8 BRPI0506496A8 (pt) 2017-11-14
BRPI0506496B1 BRPI0506496B1 (pt) 2018-10-09
BRPI0506496B8 true BRPI0506496B8 (pt) 2022-09-20

Family

ID=34910697

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506496A BRPI0506496B8 (pt) 2004-01-30 2005-01-17 composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese

Country Status (25)

Country Link
US (1) US8183230B2 (pt)
EP (1) EP1713504B1 (pt)
JP (1) JP5021318B2 (pt)
KR (1) KR100834232B1 (pt)
CN (1) CN101090735A (pt)
AR (2) AR047469A1 (pt)
AU (1) AU2005216709B2 (pt)
BR (1) BRPI0506496B8 (pt)
CA (1) CA2554346C (pt)
CO (1) CO5700794A2 (pt)
CY (1) CY1119188T1 (pt)
DK (1) DK1713504T3 (pt)
ES (1) ES2638113T3 (pt)
HU (1) HUE034099T2 (pt)
IL (1) IL176676A0 (pt)
LT (1) LT1713504T (pt)
NO (1) NO20063858L (pt)
NZ (1) NZ548236A (pt)
PL (1) PL1713504T3 (pt)
PT (1) PT1713504T (pt)
RU (1) RU2332997C2 (pt)
SI (1) SI1713504T1 (pt)
TW (1) TW200524632A (pt)
WO (1) WO2005082416A2 (pt)
ZA (1) ZA200605148B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2852716C (en) * 2011-11-29 2015-11-17 Jurox Pty Ltd Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
AU2013273764B2 (en) * 2011-11-29 2016-05-05 Zoetis Services Llc Pharmaceutical compositions
AU2014292086B2 (en) * 2013-07-19 2019-08-08 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
NL2015865B1 (en) 2015-11-27 2017-06-13 Le Vet B V Maropitant Formulation.
US11160809B2 (en) 2017-04-10 2021-11-02 Chase Therapeutics Corporation NK1-antagonist combination and method for treating synucleinopathies
BR112019028034A2 (pt) 2017-06-30 2020-07-07 Chase Therapeutics Corporation composições de antagonista de nk-1 e métodos para uso no tratamento da depressão
EP3923916A4 (en) * 2019-02-15 2022-12-21 Saol International Development Ltd. INJECTABLE PHENOL FORMULATIONS AND METHODS OF USE
EP3725298A1 (en) 2019-04-16 2020-10-21 Faes Farma, S.A. Stable and preserved pharmaceutical compositions of bilastine
CN112370451A (zh) * 2020-12-08 2021-02-19 河北科技大学 一种枸橼酸马罗匹坦包合物、注射液及制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5910510A (ja) * 1982-07-08 1984-01-20 Nippon Zenyaku Kogyo Kk 低刺激性チアムリン注射剤
JPS59152320A (ja) 1983-02-17 1984-08-31 Takeda Chem Ind Ltd 水性製剤
JPS6419737A (en) * 1987-07-15 1989-01-23 Hitachi Ltd Multilayer interconnection tape carrier
JPH039848A (ja) * 1989-06-06 1991-01-17 Canon Inc 液体噴射記録装置
DE69208877T2 (de) 1991-05-31 1996-07-25 Pfizer Chinuclidinderivate
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5886009A (en) 1992-11-12 1999-03-23 Pfizer Inc. Quinuclidine derivative as a substance P antagonist
US5393762A (en) 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
WO2000012137A1 (en) 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US6255320B1 (en) 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
AU5975700A (en) 1999-07-02 2001-01-22 Janssen Pharmaceutica N.V. Nasal formulation of an antifungal
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
AU2002254309B2 (en) * 2001-03-20 2006-02-02 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
CN1529600A (zh) * 2001-07-20 2004-09-15 �Ʒ� Nk-1受体拮抗剂在改变狗、猫和马的不需要行为中的用途
AR038576A1 (es) 2002-02-22 2005-01-19 Pharmacia Corp Formulaciones de drogas antibioticas oftalmicas que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
DE10228049A1 (de) 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
US6861526B2 (en) 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
JP2007519701A (ja) 2004-01-30 2007-07-19 ファイザー・プロダクツ・インク 麻酔回復を改善するためのｎｋ−１受容体拮抗剤
MXPA06008648A (es) 2004-01-30 2006-09-04 Pfizer Prod Inc Composiciones farmaceuticas de antagonistas del receptor de neuroquinina y ciclodextrina y metodos para una tolerancia mejorada en el sitio de inyeccion.
JP2007519710A (ja) 2004-02-02 2007-07-19 ファイザー・プロダクツ・インク １−（２Ｓ，３Ｓ）−２−ベンズヒドリル−Ｎ−（５−ｔｅｒｔ−ブチル−２−メトキシベンジル）キヌクリジン−３−アミンの製造方法

Also Published As

Publication number Publication date
EP1713504B1 (en) 2017-06-07
KR20060128973A (ko) 2006-12-14
RU2332997C2 (ru) 2008-09-10
TW200524632A (en) 2005-08-01
LT1713504T (lt) 2017-09-11
CA2554346C (en) 2009-11-17
SI1713504T1 (sl) 2017-10-30
EP1713504A2 (en) 2006-10-25
BRPI0506496A (pt) 2007-02-13
JP2007519703A (ja) 2007-07-19
US8183230B2 (en) 2012-05-22
HUE034099T2 (en) 2018-01-29
KR100834232B1 (ko) 2008-05-30
ZA200605148B (en) 2007-10-31
CO5700794A2 (es) 2006-11-30
WO2005082416A3 (en) 2006-07-27
AR109357A2 (es) 2018-11-21
ES2638113T3 (es) 2017-10-18
NZ548236A (en) 2010-02-26
CY1119188T1 (el) 2018-02-14
IL176676A0 (en) 2006-10-31
AR047469A1 (es) 2006-01-18
RU2006127422A (ru) 2008-03-10
BRPI0506496A8 (pt) 2017-11-14
PT1713504T (pt) 2017-08-29
WO2005082416A2 (en) 2005-09-09
AU2005216709B2 (en) 2008-02-07
NO20063858L (no) 2006-10-19
PL1713504T3 (pl) 2017-12-29
US20070155697A1 (en) 2007-07-05
AU2005216709A1 (en) 2005-09-09
CA2554346A1 (en) 2005-09-09
JP5021318B2 (ja) 2012-09-05
CN101090735A (zh) 2007-12-19
DK1713504T3 (en) 2017-08-07
BRPI0506496B1 (pt) 2018-10-09

Similar Documents

Publication Publication Date Title
BRPI0506496B8 (pt) composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese
EP2305695A3 (en) Macrocyclic inhibitors of Hepatitis C virus replication
AR054064A1 (es) Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas
BRPI0512985A (pt) derivados de 3-carbamoil-2-piridona
BRPI0508933A (pt) composições para entrega tópica
BR0213522A (pt) Composto, composição farmacêutica, métodos de inibir a hiv integrase e para prevenir ou tratar a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids em um paciente, e, combinação útil para tratar ou prevenir a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids
US20100292199A1 (en) Transcutaneous pharmaceutical compositions containing a steroid hormone
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0518781A2 (pt) formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, e, uso de um composto
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
BRPI0714761B8 (pt) formulações compreendendo compostos cíclicos
BRPI0514250A (pt) uso de um composto, composição farmacêutica que compreende o mesmo, compostos e método de tratamento
BR0309057A (pt) Formulações lìquidas com baixa dosagem em entecavir e uso
EP1790341A4 (en) MEDICINE WITH ANALGESIC EFFECTS
BRPI0515555A (pt) composição farmacêutica compreendendo éster de temozolomida
NI202100031A (es) Formulación basada en ciclodextrina de un inhibidor de bcl-2
BRPI0409878A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
JP2014114249A (ja) 基剤、及び皮膚外用剤
JP5743375B2 (ja) カンジダ症予防又は治療剤
AR037543A1 (es) Metodo para la terapia del cancer y composicion farmaceutica
JP7156825B2 (ja) 外用医薬組成物
AR066667A1 (es) Composiciones farmaceuticas que comrenden la combinacion de un agente derivado hidrogenado de lipstatina y un agente inhibidor de hmg coa reductasa
AR125886A1 (es) Composición farmacéutica para prevenir o tratar la fibrosis
JP5376889B2 (ja) カンジダ症予防又は治療剤

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: PAH USA 15 LLC (US)

B25D Requested change of name of applicant approved

Owner name: ZOETIS P LLC (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: ZOETIS SERVICES LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: ZOETIS SERVICES LLC (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/724 (2000.01), A61K 47/40 (1990.01), A61K

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/10/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/01/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22E Other requirements [chapter 22.5 patent gazette]

Free format text: FORMULADA EXIGENCIA PARA ADEQUACAO OU CUMPRIMENTO DE DISPOSICOES LEGAIS NO PRAZO DE 60 (SESSENTA) DIAS DESTA DATA.

B16B Notification of grant cancelled [chapter 16.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 16.3 NA RPI NO 2629 DE 25/05/2021 POR TER SIDO INDEVIDA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: RETIFICACAO REF. RPI 2492, DE 09/10/2018. PRAZO DE VALIDADE: 10 ANOS CONTADOS A PARTIR DE 09/10/2018, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME A ADI 5.529/DF, COM APOSTILAMENTO DO PRAZO DE VALIDADE DA PROTECAO DA MATERIA RELATIVA A PRODUTOS E PROCESSOS FARMACEUTICOS E EQUIPAMENTOS E/OU MATERIAIS DE USO EM SAUDE, PARA APLICACAO EM HUMANOS.